Login to Your Account



Pfizer's palbociclib gets accelerated nod in metastatic breast cancer

By Jennifer Boggs
Managing Editor

Tuesday, February 3, 2015

As widely expected, Pfizer Inc.'s cyclin-dependent kinase inhibitor palbociclib won a much-anticipated accelerated approval, with an FDA nod for use in advanced or metastatic breast cancer coming late Tuesday afternoon.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription